Phaseline

Companies › ArthroBiologix

ArthroBiologix: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Immunology, Oncology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Platelet-rich plasma (PRP)
Autologous platelet-rich plasma derived from patient blood
–Phase 4Osteoarthritis, Knee; Olfactory Dysfunction; Breast Cancer; Trochanteric Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04111718Platelet-rich plasma (PRP)Phase 4Osteoarthritis, KneeImmunologyDec 2025
NCT05812924Platelet-rich plasma (PRP)Phase 2Breast CancerOncologySep 2026
NCT07151703Platelet-rich plasma (PRP)Phase 3Olfactory DysfunctionOtherDec 2027
NCT07396246Platelet-rich plasma (PRP)Phase 2Trochanteric SyndromeOtherDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ALK-Abelló CellTherX Kolon TissueGene Gradalis Doron Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.